Sanofi’s $3.2bn move for Translate Bio leaves Arcturus as one of the few affordable independent mRNA players.
And four other potential targets that could make sense for the beleaguered group.
The group does not let the grass grow under its feet, acquiring Tidal Therapeutics before its bigger Synthorx buy has proven itself.
The company’s lead cystic fibrosis asset fails, shifting the focus to the Sanofi-partnered Covid-19 vaccine.
Ionis’s inhaled antisense candidate shows promising signs, with Arrowhead and Translate Bio also in the running.
Pfizer/Biontech’s preprint might prove academic as investors look to pivotal study designs and readouts.
The new price for its Covid-19 vaccine is lower than earlier deals – but arguably not by much.